welcome to neurology live® Brain game! Aired every Sunday morning, this weekly quiz series features quizzes on a variety of clinical and historical neurology topics written by physicians, clinicians, and experts in the field of neurological care and advocacy. Questions are raised.
Dementia and Alzheimer’s disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week’s question theme is 2022 Neurology News.
Click here to check out previous iterations of Brain Games.
Interested in submitting a quiz question? Contact Editor-in-Chief Matt Hoffman by email: mhoffman@neurologylive.com.
Earlier this year, daridorexant was approved by the FDA for which of the following diseases?
In 2022, Biogen and Eisai’s investigational lecanemab will emerge as a promising treatment for Alzheimer’s disease and could become the second treatment approved for Alzheimer’s disease after aducanumab (Aduhelm, Biogen) There is a nature. Which drug was last approved for AD before aducanumab?
In September, the FDA made a landmark decision to approve Amylyx Pharmaceuticals’ AMX0035 (Relyvrio) for the treatment of amyotrophic lateral sclerosis (ALS). It was due to determine another ALS candidate in January of this year but has extended the review period, tofersen. What genetic causes of ALS are targeted by tofersen?
How was this week’s quiz? Please let us know your answers to the survey below. Don’t forget to share and compare your results with your friends!
How many questions did you get right?
